Artizan Biosciences
Microbiome

Artizan Biosciences is developing therapeutics that can eliminate disease-causing bacteria in the gut microbiome. The full write-up should be: Artizan Biosciences is developing therapeutics that can eliminate disease-causing bacteria in the gut microbiome. Artizan leverages a platform technology called IgAseq that can tag and uncover the “bad-actor” bacteria in various diseases, with an initial focus on IBD/Crohn’s disease. The technology was developed in the labs of Noah Palm and Richard Flavell at Yale University.


University
Yale University
Sector
Life Science
Status
Active
Initial Investment Stage
Early
Team